MENU
+Compare
RGEN
Stock ticker: NASDAQ
AS OF
Nov 21 closing price
Price
$162.51
Change
+$8.15 (+5.28%)
Capitalization
9.15B

RGEN Repligen Corp Forecast, Technical & Fundamental Analysis

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more

Industry: #Biotechnology
RGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for RGEN with price predictions
Nov 21, 2025

RGEN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for RGEN turned positive on November 21, 2025. Looking at past instances where RGEN's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 18, 2025. You may want to consider a long position or call options on RGEN as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for RGEN moved above the 200-day moving average on October 31, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 187 cases where RGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RGEN moved out of overbought territory on October 27, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RGEN broke above its upper Bollinger Band on November 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.394) is normal, around the industry mean (9.098). RGEN's P/E Ratio (8130.000) is considerably higher than the industry average of (160.120). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.561). RGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (12.903) is also within normal values, averaging (111.040).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
RGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

RGEN is expected to report earnings to fall 3.67% to 44 cents per share on February 25

Repligen Corp RGEN Stock Earnings Reports
Q4'25
Est.
$0.44
Q3'25
Beat
by $0.04
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.03
The last earnings report on October 28 showed earnings per share of 46 cents, beating the estimate of 41 cents. With 892.07K shares outstanding, the current market capitalization sits at 9.15B.
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
41 Seyon Street
Phone
+1 781 250-0111
Employees
1783
Web
https://www.repligen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACLC76.171.06
+1.41%
American Century Large Cap Equity ETF
INCM27.750.17
+0.62%
Franklin Income Focus ETF
EMHC25.560.05
+0.18%
State Street® SPDR® Blmbg EM USD Bd ETF
IHY21.790.03
+0.11%
VanEck Intl Hi Yld Bd ETF
COLO35.57-0.79
-2.17%
Global X MSCI Colombia ETF

RGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+5.34%
DHR - RGEN
67%
Closely correlated
+2.34%
A - RGEN
65%
Loosely correlated
+4.27%
BIO - RGEN
60%
Loosely correlated
+4.31%
MTD - RGEN
59%
Loosely correlated
+3.78%
TMO - RGEN
58%
Loosely correlated
+2.57%
More

Groups containing RGEN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+5.34%
RGEN
(3 stocks)
92%
Closely correlated
+3.98%
Pharmaceuticals: Other
(103 stocks)
61%
Loosely correlated
+2.13%
Pharmaceuticals
(378 stocks)
60%
Loosely correlated
+1.62%